Pancreatic Cancer Research beyond DNA Mutations
Pancreatic ductal adenocarcinoma (PDAC) is caused by genetic mutations in four genes:
KRAS proto-oncogene and GTPase (KRAS), tumor protein P53 (TP53), cyclin-dependent …
KRAS proto-oncogene and GTPase (KRAS), tumor protein P53 (TP53), cyclin-dependent …
An update on molecular research of pancreatic adenocarcinoma
Introduction: This review provides an overview of the molecular mechanisms and pathways
known to enhance development and progression of pancreatic ductal adenocarcinoma …
known to enhance development and progression of pancreatic ductal adenocarcinoma …
[PDF][PDF] Short Report—Lethal and Aggressive Pancreatic Cancer: Molecular Pathogenesis, Cellular Heterogeneity, and Biomarkers of Pancreatic Ductal …
S Kannan, P Shaik Syed Ali… - Eur. Rev. Med …, 2022 - europeanreview.org
This short report describes the carcinogenesis of the pancreas leading to pancreatic ductal
adenocarcinoma (PDAC) determined by molecular, cellular, and functional heterogeneity …
adenocarcinoma (PDAC) determined by molecular, cellular, and functional heterogeneity …
Molecular pathogenesis of pancreatic cancer
TJ Grant, K Hua, A Singh - Progress in molecular biology and translational …, 2016 - Elsevier
Pancreatic cancers arise predominantly from ductal epithelial cells of the exocrine pancreas
and are of the ductal adenocarcinoma histological subtype (PDAC). PDAC is an aggressive …
and are of the ductal adenocarcinoma histological subtype (PDAC). PDAC is an aggressive …
Biological characteristics of pancreatic ductal adenocarcinoma: Initiation to malignancy, intracellular to extracellular
O Li, L Li, Y Sheng, K Ke, J Wu, Y Mou, M Liu, W Jin - Cancer Letters, 2023 - Elsevier
Pancreatic ductal adenocarcinoma (PDAC) is a highly life-threatening tumour with a low
early-detection rate, rapid progression and a tendency to develop resistance to …
early-detection rate, rapid progression and a tendency to develop resistance to …
Genomic heterogeneity of pancreatic ductal adenocarcinoma and its clinical impact
ML Gutiérrez, L Muñoz-Bellvís, A Orfao - Cancers, 2021 - mdpi.com
Simple Summary Although much progress has been made in recent years in the clinical
management of solid tumors, pancreatic ductal adenocarcinoma (PDAC) remains a …
management of solid tumors, pancreatic ductal adenocarcinoma (PDAC) remains a …
Novel therapeutic approaches in pancreatic cancer based on genomic alterations
S Yachida - Current pharmaceutical design, 2012 - ingentaconnect.com
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive and devastating disease, which
is characterized by invasiveness and dissemination to the lymphatic system and distant …
is characterized by invasiveness and dissemination to the lymphatic system and distant …
Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma
Y Qian, Y Gong, Z Fan, G Luo, Q Huang… - Journal of hematology & …, 2020 - Springer
Pancreatic ductal adenocarcinoma (PDAC) is a malignancy characterized by a poor
prognosis and high mortality rate. Genetic mutations and altered molecular pathways serve …
prognosis and high mortality rate. Genetic mutations and altered molecular pathways serve …
Recent advances in precision medicine for pancreatic ductal adenocarcinoma
H Hayashi, T Higashi, T Miyata… - Annals of …, 2021 - Wiley Online Library
Pancreatic ductal adenocarcinoma (PDAC) is one of the leading causes of cancer mortality
worldwide. Although advances in systemic chemotherapy for PDAC have improved survival …
worldwide. Although advances in systemic chemotherapy for PDAC have improved survival …
RETRACTED: Biotherapeutic approaches to pancreatic cancer
L Rosenberg, M Lipsett - Expert Opinion on Biological Therapy, 2003 - Taylor & Francis
RETRACTED: Biotherapeutic approaches to pancreatic cancer Page 1 Review 2003 © Ashley
Publications Ltd ISSN 1471-2598 319 Ashley Publications www.ashley-pub.com 1. Introduction …
Publications Ltd ISSN 1471-2598 319 Ashley Publications www.ashley-pub.com 1. Introduction …